Therapy Overview & Search
This is the search page for all therapy, you can search for name or condition
Filter By
Therapeutic Area
Manufacturer
SORT BY
-
bosentan
Ambrisentan is an endothelin receptor antagonist approved to treat adults and children 3 years and older with WHO group 1 pulmonary arterial hypertension. By increasing pulmonary vasodilation, it can improve exercise tolerance and quality of life.Manufacturer:MiscRoute of Administration:OralSite of Care:OutpatientWebsite:phone:1-866-359-2612Approved Indication:
- treatment of pulmonary arterial hypertension (WHO group 1) in adults to improve exercise ability and to decrease clinical worsening
- treatment of pulmonary arterial hypertension (WHO group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance which is expected to result in an improvement in exercise ability
Conditions:
- Pulmonary Arterial Hypertension
-
calcitriol
Calcitriol is a synthetic vitamin D analog that helps regulate the absorption of calcium from the gastrointestinal tract and its use in the body.Manufacturer:MiscRoute of Administration:OralSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
- managing secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15-55 mL/min)
- managing hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis
- managing hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism
Conditions:
- Hypocalcemia
- Secondary Hyperparathyroidism
Therapeutic Area:
- Oncology
-
CellCept (mycophenolate mofetil)
CellCept (mycophenolate mofetil) is a prodrug of mycophenolic acid, an antiproliferative agent approved to prevent rejection of a transplanted organ. Because of its mechanism, CellCept is also widely used in the management of certain autoimmune disorders.Manufacturer:GenentechRoute of Administration:OralSite of Care:OutpatientWebsite:Approved Indication:
prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogenic kidney, heart, or liver transplants, in combination with other immunosuppressants
Conditions:
- Solid Organ Transplant
Therapeutic Area:
- Gastroenterology
- Rheumatology
- Dermatology
- Hepatology
- Nephrology
-
Cimzia (certolizumab pegol)
Cimzia (certolizumab pegol) is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthitis, Crohn’s disease, and plaque psoriasis.Manufacturer:UCB, Inc.Route of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:1-866-424-6942Approved Indication:
- reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy
- treatment of adults with moderately to severely active rheumatoid arthritis/strong>
- treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
- treatment of adult patients with active psoriatic arthritis
- treatment of adults with active ankylosing spondylitis
- treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation
- treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
Conditions:
- Ankylosing Spondylitis
- Crohn’s Disease
- Juvenile Idiopathic Arthritis
- Non-Radiographic Axial Spondyloarthritis
- Plaque Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
Therapeutic Area:
- Dermatology
- Gastroenterology
- Rheumatology
-
cinacalcet
Cinacalcet is a calcium-sensing receptor agonist that lowers circulating parathyroid hormone and serum calcium levels to help prevent progressive bone disease.Manufacturer:MiscRoute of Administration:OralSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
- secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis
- hypercalcemia in adult patients with parathyroid carcinoma
- hypercalcemia in adult patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels but who are unable to undergo parathyroidectomy
Conditions:
- Hypercalcemia
- Secondary Hyperparathyroidism
Therapeutic Area:
- Oncology
-
Creon (pancrelipase)
Creon (pancrelipase) is a pancreatic enzyme product that contains a mixture of lipases, proteases, and amylases. By mimicing the digestive enzymes naturally secreated by the pancreas, Creon aids in the digestion of fat from meals in patients who are unable to produce enough pancreatic enzymes.Manufacturer:AbbVieRoute of Administration:OralSite of Care:OutpatientWebsite:Approved Indication:
treatment of exocrine pancreatic insufficiency in adult and pediatric patients
Conditions:
- Exocrine Pancreatic Insufficiency
Therapeutic Area:
- Gastroenterology
-
Cresemba (isavuconazonium sulfate)
Cresemba (isavuconazonium sulfate) is an azole antifungal medication given orally or intravenously to treat invasive aspergillosis or invasive mucormycosis.Manufacturer:AstellasRoute of Administration:Oral, IntravenousSite of Care:OutpatientWebsite:phone:1-800-477-6472Approved Indication:
treatment of invasive aspergillosis and invasive mucormycosis in adults and pediatric patients 6 years of age and older who weigh at least 16 kilograms
Conditions:
- Invasive Aspergillosis
- Mucormycosis
-
Cyltezo (adalimumab-adbm)
Cyltezo (adalimumab-adbm) is an FDA-approved, citrate-free, interchangeable biosimilar to Humira. Like Humira, Cyltezo is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and panuveitis.Manufacturer:Boehringer IngelheimRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:1-833-295-8396Approved Indication:
- reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
- reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
- reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
- reducing signs and symptoms in adult patients with active ankylosing spondylitis
- treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older
- treatment of moderately to severely active ulcerative colitis in adult patients
- treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
- treatment of moderate to severe hidradenitis suppurativa in adult patients
- treatment of non-infectious intermediate, posterior, and panuveitis in adult patients
Conditions:
- Ankylosing Spondylitis
- Crohn’s Disease
- Hidradenitis Suppurativa
- Juvenile Idiopathic Arthritis
- Plaque Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Ulcerative Colitis
- Uveitis
Therapeutic Area:
- Dermatology
- Gastroenterology
- Rheumatology
-
Desferal (deferoxamine)
Desferal (deferoxamine) is an iron-chelating agent given by intravenous or subcutaneous infusion to lower iron levels in the blood.Manufacturer:NovartisRoute of Administration:Subcutaneous, IntravenousSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
- as an adjunct to standard measures for the treatment of acute iron intoxication
- treatment of transfusional iron overload in patients with chronic anemia
Conditions:
- Sickle Cell Disease
- Anemia
-
Dificid (fidaxomicin)
Dificid (fidaxomicin) is a macrolide antibiotic approved to treat the diarrhea caused by infection with Clostridium difficile in adults and children 6 months of age and older.Manufacturer:MerckRoute of Administration:OralSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
treatment of Clostridium difficile-associated diarrhea in adults and pediatric patients 6 months of age and older
Conditions:
- C. Difficile Diarrhea
Therapeutic Area:
- Infectious disease
-
Droxia (hydroxyurea)
Droxia (hydroxyurea) is an antimetabolite that slows down cell growth. In sickle cell diease, it is approved to reduce the number of painful crises and the need for blood transfusions.Manufacturer:Waylis TherapeuticsRoute of Administration:OralSite of Care:OutpatientWebsite:phone:888-218-8897Approved Indication:
- reducing the frequency of painful crises and the need for blood transfusions in patients with sickle cell anemia with recurrent moderate to severe painful crises
Conditions:
- Sickle Cell Disease
-
Dupixent
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut ut imperdiet orci. Cras sed augue purus. Sed quam est, volutpat ut urna vulputate, viverra maximus arcu.Manufacturer:Sanofi | RegeneronRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:123.222.2191Enrollment Forms:Patient Support FormApproved Indication:
- treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
- add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma
- add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps
- treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kilograms, with eosinophilic esophagitis
- treatment of adult patients with prurigo nodularis
- add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease and an eosinophilic phenotype
- treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment
Therapeutic Area:
- Gastroenterology
- Rheumatology
- Dermatology